Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 20 |
| List of Tables | 18 | 3 |
| List of Figures | 21 | 1 |
| Introduction | 22 | 1 |
| Global Markets Direct Report Coverage | 22 | 1 |
| Ulcerative Colitis Overview | 23 | 1 |
| Therapeutics Development | 24 | 2 |
| Pipeline Products for Ulcerative Colitis Overview | 24 | 1 |
| Pipeline Products for Ulcerative Colitis Comparative Analysis | 25 | 1 |
| Ulcerative Colitis Therapeutics under Development by Companies | 26 | 7 |
| Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes | 33 | 1 |
| Ulcerative Colitis Pipeline Products Glance | 34 | 4 |
| Late Stage Products | 34 | 1 |
| Clinical Stage Products | 35 | 1 |
| Early Stage Products | 36 | 1 |
| Unknown Stage Products | 37 | 1 |
| Ulcerative Colitis Products under Development by Companies | 38 | 9 |
| Ulcerative Colitis Products under Investigation by Universities/Institutes | 47 | 1 |
| Ulcerative Colitis Companies Involved in Therapeutics Development | 48 | 76 |
| 4D Pharma Plc | 48 | 1 |
| AbbVie Inc | 49 | 1 |
| Abivax S.A. | 50 | 1 |
| Advinus Therapeutics Ltd | 51 | 1 |
| Aerpio Therapeutics, Inc. | 52 | 1 |
| Am-Pharma B.V. | 53 | 1 |
| Amgen Inc. | 54 | 1 |
| Aptevo Therapeutics Inc | 55 | 1 |
| Arena Pharmaceuticals, Inc. | 56 | 1 |
| Atlantic Healthcare Plc | 57 | 1 |
| Bionovis SA | 58 | 1 |
| Bristol-Myers Squibb Company | 59 | 1 |
| Celgene Corporation | 60 | 1 |
| Cellceutix Corporation | 61 | 1 |
| ChemoCentryx, Inc. | 62 | 1 |
| ChironWells GmbH | 63 | 1 |
| Coherus BioSciences, Inc. | 64 | 1 |
| Cosmo Pharmaceuticals NV | 65 | 1 |
| Dr. Falk Pharma GmbH | 66 | 1 |
| EA Pharma Co Ltd | 67 | 1 |
| Eli Lilly and Company | 68 | 1 |
| Enceladus Pharmaceuticals BV | 69 | 1 |
| enGene, Inc | 70 | 1 |
| Enterome Bioscience SA | 71 | 1 |
| Epirus Biopharmaceuticals, Inc. | 72 | 1 |
| Flexion Therapeutics, Inc. | 73 | 1 |
| Galapagos NV | 74 | 1 |
| Genentech, Inc. | 75 | 1 |
| Genor BioPharma Co Ltd | 76 | 1 |
| GlaxoSmithKline Plc | 77 | 1 |
| GW Pharmaceuticals Plc | 78 | 1 |
| iCo Therapeutics Inc. | 79 | 1 |
| Idera Pharmaceuticals, Inc. | 80 | 1 |
| InDex Pharmaceuticals AB | 81 | 1 |
| Innovate Biopharmaceuticals, Inc. | 82 | 1 |
| INOXIA Lifesciences GmbH | 83 | 1 |
| Intas Pharmaceuticals Ltd. | 84 | 1 |
| Johnson &Johnson | 85 | 1 |
| Kaken Pharmaceutical Co., Ltd. | 86 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 87 | 1 |
| LIPID THERAPEUTICS GmbH | 88 | 1 |
| Lycera Corp. | 89 | 1 |
| Medestea Research &Production S.p.A. | 90 | 1 |
| Merck &Co., Inc. | 91 | 1 |
| Miyarisan Pharmaceutical Company, Ltd | 92 | 1 |
| Momenta Pharmaceuticals, Inc. | 93 | 1 |
| Morphotek, Inc. | 94 | 1 |
| Mycenax Biotech Inc. | 95 | 1 |
| NeuClone Pty Ltd | 96 | 1 |
| Oncobiologics, Inc. | 97 | 1 |
| OSE Immunotherapeutics | 98 | 1 |
| Pfizer Inc. | 99 | 1 |
| Pluristem Therapeutics Inc. | 100 | 1 |
| ProtAb Ltd | 101 | 1 |
| Protagonist Therapeutics Inc. | 102 | 1 |
| Protalix BioTherapeutics, Inc. | 103 | 1 |
| Qu Biologics Inc. | 104 | 1 |
| Re-Pharm Limited | 105 | 1 |
| Rebiotix Inc. | 106 | 1 |
| Sandoz International GmbH | 107 | 1 |
| Seres Therapeutics, Inc. | 108 | 1 |
| Shire Plc | 109 | 1 |
| Sigmoid Pharma Limited | 110 | 1 |
| Stelic Institute &Co., Inc. | 111 | 1 |
| Sterna biologicals Gmbh &Co KG | 112 | 1 |
| Synergy Pharmaceuticals, Inc. | 113 | 1 |
| Synlogic Inc | 114 | 1 |
| Takeda Pharmaceutical Company Limited | 115 | 1 |
| Therapeutic Proteins International, LLC | 116 | 1 |
| Therapix Biosciences Ltd. | 117 | 1 |
| Theravance Biopharma, Inc. | 118 | 1 |
| Tillotts Pharma AG | 119 | 1 |
| TopiVert Ltd | 120 | 1 |
| Trino Therapeutics Limited | 121 | 1 |
| UCB S.A. | 122 | 1 |
| Ventria Bioscience | 123 | 1 |
| Ulcerative Colitis Therapeutics Assessment | 124 | 14 |
| Assessment by Monotherapy Products | 124 | 1 |
| Assessment by Target | 125 | 4 |
| Assessment by Mechanism of Action | 129 | 5 |
| Assessment by Route of Administration | 134 | 2 |
| Assessment by Molecule Type | 136 | 2 |
| Drug Profiles | 138 | 256 |
| ABS-11 Drug Profile | 138 | 1 |
| ABX-464 Drug Profile | 139 | 2 |
| adalimumab Drug Profile | 141 | 7 |
| adalimumab biosimilar Drug Profile | 148 | 2 |
| adalimumab biosimilar Drug Profile | 150 | 1 |
| adalimumab biosimilar Drug Profile | 151 | 1 |
| adalimumab biosimilar Drug Profile | 152 | 1 |
| adalimumab biosimilar Drug Profile | 153 | 1 |
| adalimumab biosimilar Drug Profile | 154 | 2 |
| adalimumab biosimilar Drug Profile | 156 | 2 |
| adalimumab biosimilar Drug Profile | 158 | 1 |
| adalimumab biosimilar Drug Profile | 159 | 1 |
| adalimumab biosimilar Drug Profile | 160 | 1 |
| adalimumab biosimilar Drug Profile | 161 | 1 |
| AKB-4924 Drug Profile | 162 | 1 |
| AKP-11 Drug Profile | 163 | 2 |
| alicaforsen sodium Drug Profile | 165 | 1 |
| Anatabine Drug Profile | 166 | 3 |
| Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer Drug Profile | 169 | 1 |
| apremilast Drug Profile | 170 | 10 |
| AW/EPO-002 Drug Profile | 180 | 1 |
| AW/EPO-003 Drug Profile | 181 | 1 |
| AW/EPOPD-01 Drug Profile | 182 | 1 |
| AW/EPOPD-02 Drug Profile | 183 | 1 |
| AW/EPOPD-06 Drug Profile | 184 | 1 |
| bertilimumab Drug Profile | 185 | 3 |
| bimekizumab Drug Profile | 188 | 1 |
| Biologic for Ulcerative Colitis and Crohn's Disease Drug Profile | 189 | 1 |
| BMS-986166 Drug Profile | 190 | 1 |
| BMS-986184 Drug Profile | 191 | 1 |
| brilacidin tetrahydrochloride Drug Profile | 192 | 9 |
| budesonide Drug Profile | 201 | 3 |
| carotegrast Drug Profile | 204 | 2 |
| CBM-588 Drug Profile | 206 | 2 |
| CCX-507 Drug Profile | 208 | 1 |
| cobitolimod Drug Profile | 209 | 4 |
| cyclosporine CR Drug Profile | 213 | 1 |
| D-9030 Drug Profile | 214 | 1 |
| DNVX-078 Drug Profile | 215 | 1 |
| DNX-514 Drug Profile | 216 | 1 |
| dolcanatide Drug Profile | 217 | 3 |
| Drug to Inhibit Calpain-2 for Crohn's Diseases and Ulcerative Colitis Drug Profile | 220 | 1 |
| EB-420 Drug Profile | 221 | 1 |
| EFFI-7H Drug Profile | 222 | 2 |
| EG-10 Drug Profile | 224 | 1 |
| EG-12 Drug Profile | 225 | 1 |
| enalaprilat Drug Profile | 226 | 1 |
| ES-210 Drug Profile | 227 | 1 |
| etanercept biosimilar Drug Profile | 228 | 2 |
| etrasimod arginine Drug Profile | 230 | 2 |
| etrolizumab Drug Profile | 232 | 2 |
| filgotinib Drug Profile | 234 | 10 |
| FX-003 Drug Profile | 244 | 1 |
| golimumab biosimilar Drug Profile | 245 | 1 |
| golimumab biosimilar Drug Profile | 246 | 1 |
| golimumab biosimilar Drug Profile | 247 | 1 |
| GSK-2982772 Drug Profile | 248 | 1 |
| GWP-42003 Drug Profile | 249 | 2 |
| hyaluronate sodium Drug Profile | 251 | 1 |
| IAC-VITA Drug Profile | 252 | 2 |
| IMO-9200 Drug Profile | 254 | 2 |
| infliximab Drug Profile | 256 | 4 |
| infliximab biosimilar Drug Profile | 260 | 1 |
| infliximab biosimilar Drug Profile | 261 | 1 |
| infliximab biosimilar Drug Profile | 262 | 1 |
| infliximab biosimilar Drug Profile | 263 | 3 |
| infliximab biosimilar Drug Profile | 266 | 1 |
| infliximab biosimilar Drug Profile | 267 | 3 |
| infliximab biosimilar Drug Profile | 270 | 1 |
| infliximab biosimilar Drug Profile | 271 | 1 |
| INN-108 Drug Profile | 272 | 1 |
| INV-88 Drug Profile | 273 | 1 |
| KAG-308 Drug Profile | 274 | 1 |
| KANAb-071 Drug Profile | 275 | 2 |
| KHK-4083 Drug Profile | 277 | 1 |
| kPPF-1 Drug Profile | 278 | 1 |
| lipidated tacrolimus Drug Profile | 279 | 1 |
| LT-0011 Drug Profile | 280 | 1 |
| LT-02 Drug Profile | 281 | 2 |
| LY-3074828 Drug Profile | 283 | 1 |
| LYC-30937 Drug Profile | 284 | 2 |
| mesalamine Drug Profile | 286 | 2 |
| mesalamine Drug Profile | 288 | 1 |
| mesalamine Drug Profile | 289 | 1 |
| mesalamine DR Drug Profile | 290 | 1 |
| mesalamine ER Drug Profile | 291 | 2 |
| mongersen sodium Drug Profile | 293 | 3 |
| Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease Drug Profile | 296 | 1 |
| naltrexone hydrochloride Drug Profile | 297 | 3 |
| NRG-4 Drug Profile | 300 | 1 |
| ozanimod hydrochloride Drug Profile | 301 | 7 |
| P-Dex Drug Profile | 308 | 1 |
| PF-06480605 Drug Profile | 309 | 1 |
| PH-44 Drug Profile | 310 | 1 |
| PH-46A Drug Profile | 311 | 1 |
| PH-5 Drug Profile | 312 | 1 |
| PNQ-201 Drug Profile | 313 | 1 |
| prednisolone sodium phosphate Drug Profile | 314 | 2 |
| Prozumab Drug Profile | 316 | 1 |
| PTG-100 Drug Profile | 317 | 2 |
| QBECO-SSI Drug Profile | 319 | 4 |
| ranibizumab biosimilar Drug Profile | 323 | 1 |
| RBX-2660 Drug Profile | 324 | 3 |
| RBX-8225 Drug Profile | 327 | 1 |
| Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis Drug Profile | 328 | 3 |
| Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis Drug Profile | 331 | 1 |
| Recombinant Protein for Crohn s Disease and Ulcerative Colitis Drug Profile | 332 | 1 |
| RG-7880 Drug Profile | 333 | 1 |
| risankizumab Drug Profile | 334 | 3 |
| Rosburix Drug Profile | 337 | 1 |
| RP-0217 Drug Profile | 338 | 1 |
| SB-012 Drug Profile | 339 | 1 |
| SER-287 Drug Profile | 340 | 2 |
| SER-301 Drug Profile | 342 | 1 |
| SHP-647 Drug Profile | 343 | 2 |
| Small Molecule to Agonize Mu Opioid Receptor for Crohn's Disease and Ulcerative Colitis Drug Profile | 345 | 1 |
| Small Molecule to Agonize S1PR1 for Ulcerative Colitis Drug Profile | 346 | 1 |
| Small Molecule to Scavenge Nitric Oxide Radical for Ulcerative Colitis and Inflammation Drug Profile | 347 | 1 |
| Small Molecules for Crohn s Disease and Ulcerative Colitis Drug Profile | 348 | 1 |
| Small Molecules for Crohns Disease and Ulcerative Colitis Drug Profile | 349 | 1 |
| Small Molecules for Rheumatoid Arthritis and Ulcerative Colitis Drug Profile | 350 | 1 |
| Small Molecules to Antagonize CCR9 for Crohn's Disease and Ulcerative Colitis Drug Profile | 351 | 1 |
| Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Crohn's Disease and Ulcerative Colitis Drug Profile | 352 | 1 |
| Small Molecules to Inhibit IL-13 for Ulcerative Colitis Drug Profile | 353 | 1 |
| sodium hypochlorite Drug Profile | 354 | 1 |
| Stem Cell Therapy for Inflammatory Bowel Disease Drug Profile | 355 | 2 |
| STNM-01 Drug Profile | 357 | 1 |
| TD-1473 Drug Profile | 358 | 2 |
| TD-3504 Drug Profile | 360 | 1 |
| tofacitinib citrate Drug Profile | 361 | 11 |
| TOP-1210 Drug Profile | 372 | 1 |
| TOP-1288 Drug Profile | 373 | 2 |
| TP-10 Drug Profile | 375 | 1 |
| TRX-318 Drug Profile | 376 | 2 |
| upadacitinib tartrate Drug Profile | 378 | 2 |
| ustekinumab Drug Profile | 380 | 6 |
| VEDA-1209 Drug Profile | 386 | 1 |
| vedolizumab Drug Profile | 387 | 6 |
| VEN-120 Drug Profile | 393 | 1 |
| Ulcerative Colitis Dormant Projects | 394 | 10 |
| Ulcerative Colitis Discontinued Products | 404 | 2 |
| Ulcerative Colitis Product Development Milestones | 406 | 14 |
| Featured News &Press Releases | 406 | 1 |
| Oct 18, 2016: Results from InDex Pharmaceuticals COLLECT study well received at UEGW | 406 | 1 |
| Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG | 407 | 1 |
| Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn s Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting | 408 | 2 |
| Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies | 410 | 1 |
| Oct 15, 2016: Pfizer to Present New Data on XELJANZ (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016 | 411 | 1 |